Cour Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 65

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $105M

  • Investors
  • 9

Cour General Information

Description

Developer of an immune-modifying platform intended to achieve antigen-specific tolerance for immune-mediated disease. The company's platform offers non-biological therapeutics for acute inflammation, autoimmunity, and allergic conditions and also engages in pharmaceutical development of immunology, pathology, or cardiovascular medicinal products, enabling patients to get acute treatments for encephalitis syndromes, autoimmune disorders, infections, and heart attacks.

Contact Information

Website
www.courpharma.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 8045 North Lamon Avenue
  • Suite 1202
  • Skokie, IL 60077
  • United States
+1 (630)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Nanotechnology, Life Sciences
Corporate Office
  • 8045 North Lamon Avenue
  • Suite 1202
  • Skokie, IL 60077
  • United States
+1 (630)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cour Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC (Series A) 30-Jan-2024 $105M Completed Clinical Trials - Phase 2
1. University Spin-Out 01-Jan-2012 Completed
To view Cour’s complete valuation and funding history, request access »

Cour Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series A
To view Cour’s complete cap table history, request access »

Cour Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of an immune-modifying platform intended to achieve antigen-specific tolerance for immune-mediated disease. Th
Drug Discovery
Skokie, IL
65 As of 2025

Cambridge, MA

Cherry Hill, NJ
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cour Competitors (3)

One of Cour’s 3 competitors is AnTolRx, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Venture Capital-Backed Cambridge, MA
Bioincept Venture Capital-Backed Cherry Hill, NJ
IM Therapeutics Venture Capital-Backed Woburn, MA
You’re viewing 3 of 3 competitors. Get the full list »

Cour Patents

  • 71

    Total Documents Applications and Grants

  • Total Patents Families

  • 22

    Granted

  • 40

    Pending

  • Expiring in next 12 mo

Cour Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023263417-A1 Tolerizing immune modifying nanoparticles for overcoming the immunogenicity of therapeutic vectors and proteins Pending 29-Apr-2022
EP-4514320-A1 Tolerizing immune modifying nanoparticles for overcoming the immunogenicity of therapeutic vectors and proteins Pending 29-Apr-2022
AU-2022397397-A1 Preparation of tolerizing nanoparticles for the treatment of peanut allergy Pending 24-Nov-2021
CA-3239024-A1 Preparation of tolerizing nanoparticles for the treatment of peanut allergy Pending 24-Nov-2021
EP-4436557-A1 Preparation of tolerizing nanoparticles for the treatment of peanut allergy Pending 24-Nov-2021 A61K9/19
To view Cour’s complete patent history, request access »

Cour Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cour Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alpha Wave Global Growth/Expansion Minority
Angelini Ventures Corporate Venture Capital Minority
Bristol-Myers Squibb Corporation Minority
Chimera Capital PE/Buyout Minority
Lumira Ventures Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Cour FAQs

  • When was Cour founded?

    Cour was founded in 2012.

  • Where is Cour headquartered?

    Cour is headquartered in Skokie, IL.

  • What is the size of Cour?

    Cour has 65 total employees.

  • What industry is Cour in?

    Cour’s primary industry is Drug Discovery.

  • Is Cour a private or public company?

    Cour is a Private company.

  • What is the current valuation of Cour?

    The current valuation of Cour is .

  • What is Cour’s current revenue?

    The current revenue for Cour is .

  • How much funding has Cour raised over time?

    Cour has raised $105M.

  • Who are Cour’s investors?

    Alpha Wave Global, Angelini Ventures, Bristol-Myers Squibb, Chimera Capital, and Lumira Ventures are 5 of 9 investors who have invested in Cour.

  • Who are Cour’s competitors?

    AnTolRx, Bioincept, and IM Therapeutics are competitors of Cour.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »